Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181

BACKGROUND: Safe and effective treatments for advanced esophageal cancer are an unmet need in Japan. We report results of a subgroup analysis of Japanese patients enrolled in KEYNOTE-181, a randomized, open-label, phase 3 study of pembrolizumab versus chemotherapy as second-line therapy for patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Muro, Kei, Kojima, Takashi, Moriwaki, Toshikazu, Kato, Ken, Nagashima, Fumio, Kawakami, Hisato, Ishihara, Ryu, Ogata, Takashi, Satoh, Taroh, Iwakami, Keiichi, Han, Shirong, Yatsuzuka, Naoyoshi, Takami, Tomoko, Bhagia, Pooja, Doi, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739314/
https://www.ncbi.nlm.nih.gov/pubmed/34591237
http://dx.doi.org/10.1007/s10388-021-00877-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739314/
https://www.ncbi.nlm.nih.gov/pubmed/34591237
http://dx.doi.org/10.1007/s10388-021-00877-3

Ejemplares similares